
Sign up to save your podcasts
Or
In the early days of the COVID-19 pandemic when there were no vaccines or treatments, convalescent plasma—antibody-containing blood from people who recovered from COVID—saved countless lives through Emergency Use Authorization. In this episode: special guest host Thomas Locke of MMI Monthly: From Bench To Breakthrough discusses the evolution of CCP therapy, from emergency use during the pandemic to now, nearly five years later, crossing the finish line with recent FDA approval as a potential treatment for immunocompromised patients.
Guest:David Sullivan is a professor in Molecular Microbiology and Immunology and a researcher at the Johns Hopkins Malaria Research Institute.
Host:Thomas Locke is the host of MMI Monthly: From Bench to Breakthrough and Malaria Minute, podcasts from the department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health.
Show links and related content:Bloomberg School Researchers Support First Blood Center to Receive Full FDA Approval to Provide Convalescent Plasma for Patients Who Are Immunocompromised—Johns Hopkins Bloomberg School of Public Health
Convalescent Plasma Offers ‘Blueprint’ For Future Pandemics—The Hub
How a Boy’s Blood Stopped an Outbreak—The Wall Street Journal (Opinion)
Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel.
Contact us:Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website.
Follow us:@PublicHealthPod on Bluesky
@JohnsHopkinsSPH on Instagram
@JohnsHopkinsSPH on Facebook
@PublicHealthOnCall on YouTube
Here's our RSS feed
Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.
4.6
609609 ratings
In the early days of the COVID-19 pandemic when there were no vaccines or treatments, convalescent plasma—antibody-containing blood from people who recovered from COVID—saved countless lives through Emergency Use Authorization. In this episode: special guest host Thomas Locke of MMI Monthly: From Bench To Breakthrough discusses the evolution of CCP therapy, from emergency use during the pandemic to now, nearly five years later, crossing the finish line with recent FDA approval as a potential treatment for immunocompromised patients.
Guest:David Sullivan is a professor in Molecular Microbiology and Immunology and a researcher at the Johns Hopkins Malaria Research Institute.
Host:Thomas Locke is the host of MMI Monthly: From Bench to Breakthrough and Malaria Minute, podcasts from the department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health.
Show links and related content:Bloomberg School Researchers Support First Blood Center to Receive Full FDA Approval to Provide Convalescent Plasma for Patients Who Are Immunocompromised—Johns Hopkins Bloomberg School of Public Health
Convalescent Plasma Offers ‘Blueprint’ For Future Pandemics—The Hub
How a Boy’s Blood Stopped an Outbreak—The Wall Street Journal (Opinion)
Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel.
Contact us:Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website.
Follow us:@PublicHealthPod on Bluesky
@JohnsHopkinsSPH on Instagram
@JohnsHopkinsSPH on Facebook
@PublicHealthOnCall on YouTube
Here's our RSS feed
Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.
5 Listeners
2,050 Listeners
40 Listeners
25 Listeners
25,773 Listeners
5 Listeners
3,319 Listeners
110,802 Listeners
55,980 Listeners
90 Listeners
479 Listeners
9 Listeners
46 Listeners
1,082 Listeners
16 Listeners
4 Listeners
4,485 Listeners
390 Listeners
6,206 Listeners
24 Listeners
5,986 Listeners
15,374 Listeners
82 Listeners
65 Listeners